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Abstract
Congenital hypogonadotropic hypogonadism (CHH) is characterized by low gonadotropins and failure to progress normally
through puberty. Mutations in the gene encoding the GnRH receptor (GNRHR1) result in CHH when present as compound
heterozygous or homozygous inactivating mutations. This study identifies and characterizes the properties of two novel
GNRHR1 mutations in a family in which three brothers display normosmic CHH while their sister was unaffected. Molecular
analysis in the proband and the affected brothers revealed two novel non-synonymous missense GNRHR1 mutations,
present in a compound heterozygous state, whereas their unaffected parents possessed only one inactivating mutation,
demonstrating the autosomal recessive transmission in this kindred and excluding X-linked inheritance equivocally
suggested by the initial pedigree analysis. The first mutation at c.845 C.G introduces an Arg substitution for the conserved
Pro 282 in transmembrane domain (TMD) 6. The Pro282Arg mutant is unable to bind radiolabeled GnRH analogue. As this
conserved residue is important in receptor conformation, it is likely that the mutation perturbs the binding pocket and
affects trafficking to the cell surface. The second mutation at c.968 A.G introduces a Cys substitution for Tyr 323 in the
functionally crucial N/DPxxY motif in TMD 7. The Tyr323Cys mutant has an increased GnRH binding affinity but reduced
receptor expression at the plasma membrane and impaired G protein-coupling. Inositol phosphate accumulation assays
demonstrated absent and impaired Gaq/11 signal transduction by Pro282Arg and Tyr323Cys mutants, respectively.
Pretreatment with the membrane permeant GnRHR antagonist NBI-42902, which rescues cell surface expression of many
GNRHR1 mutants, significantly increased the levels of radioligand binding and intracellular signaling of the Tyr323Cys
mutant but not Pro282Arg. Immunocytochemistry confirmed that both mutants are present on the cell membrane albeit at
low levels. Together these molecular deficiencies of the two novel GNRHR1 mutations lead to the CHH phenotype when
present as a compound heterozygote.
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Introduction
The dynamic secretion of synchronized gonadotropin releasing
hormone (GnRH) pulses from discrete nerve terminals into the
hypophyseal portal blood is the ultimate regulatory signal of the
brain to control reproduction [1]. The GnRH receptor, present on
pituitary gonadotropes, acts to link the hypothalamus and gonads
by binding GnRH and transducing this signal intracellularly to
regulate the synthesis and secretion of the gonadotropins,
luteinizing hormone (LH) and follicle-stimulating hormone
(FSH) [2]. Dysfunction of this ligand/receptor pair disrupts
gonadotropin secretion and ultimately leads to insufficient gonadal
maturation, presenting in patients as non-syndromic and normos-
mic (with normal sense of smell) congenital hypogonadotropic
hypogonadism (CHH) [3,4].
Twenty two natural inactivating mutations of the human
GNRHR have been identified in patients with CHH and can be
classified as either partial or complete loss-of-function mutations
[4]. Partial loss-of-function mutants may have one or more of the
following traits: reduced ligand binding affinity, decreased in-
tracellular signaling capacity and decreased receptor expression at
the cell surface due to altered trafficking of nascent receptor
protein. Interestingly, many trafficking deficient mutants can be
functionally rescued following pretreatment with cell permeant
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non-peptidic GnRH antagonists (termed pharmacoperones),
which assist newly synthesized GnRHR protein to fold correctly
within the endoplasmic reticulum (ER) and be efficiently targeted
to the plasma membrane [5].
In the present study, we characterize two novel GNRHR1
missense mutations Pro282Arg and Tyr323Cys identified in
patients with normosmic CHH (nCHH), which masqueraded as
an X-linked deficiency. Measurement of membrane binding, Gaq/
11 protein signaling as well as the ability to rescue nascent receptor
trafficking show that Pro282Arg is a complete loss-of-function
mutant and Tyr323Cys is a partial loss-of-function mutant. The
presence of CHH in our compound heterozygote patients suggests
that the poor trafficking and compromised signaling of the
Tyr323Cys mutant is unable to meet the necessary molecular
demands in the gonadotrope cell to compensate for the Pro282Arg
attributed complete loss-of-function in vivo.
Materials and Methods
Ethics Statement
All the participants gave their written informed consent for
hormonal exploration and genetic analyses, in keeping with the
provisions of the French Bioethics Law and the Declaration of
Helsinki and after approval by the Bicetre Hospital ethic
committee (Comite de protection des personnes Ile de France,
Hopital Bicetre).
Hormonal Assays
We measured serum levels of LH, FSH, inhibin B, testosterone
and estradiol (E2) levels with immunoradiometric assay, enzyme-
linked immunosorbent assay, or radioimmunoassay (RIA) as
previously reported [6–8]. Briefly, the detection limits of the LH
and FSH assays were 0.15 IU/L and 0.2 IU/L, respectively. The
intra and inter-assay coefficients of variation (CVs) were, 1.5% and
5.2% for LH, 2.7% and 5.5% for FSH, respectively.
Serum total testosterone (TT) was measured with a direct
RIA on an Orion Diagnostica device (Spectria, Espoo, Finland)
with a detection limit of 0.02 ng/mL (0.06 nmol/L). The intra-
assay and inter-assay CVs were 3.8% and 4.8% at 3.3 ng/mL
and 2.6 ng/mL (11.4 and 9.1 nmol/L), respectively, and the
intra-assay and inter-assay CVs were 7.5% and 7.0% at
0.46 ng/mL and 0.35 ng/mL (1.6 and 1.2 nmol/L), respective-
ly, for TT.
Serum total E2 was measured with a sensitive direct RIA on an
Orion Diagnostica device (Spectria). The detection limit was 2 pg/
mL (7.3 pmol/L). The intra-assay and the inter-assay CVs were
2.8% and 5.8% at 23.5 pg/mL and 25.4 pg/mL (87 pmol/L and
94 pmol/L), respectively, and the intra-assay and inter-assay CVs
were 18.1% and 17.6% at 4.6 pg/mL and 3.3 pg/mL (17 pmol/L
and 12 pmol/L), respectively, for serum total E2.
Reagents
NBI-42902 (1-(2,6-difluorobenzyl)-3-[(2R)-amino-2-phenethyl]-
5-(2-fluoro-3-methoxyphenyl)-6-methyluracil) was generously pro-
vided by Neurocrine Biosciences (San Diego, CA). His5-D-Tyr6-
GnRH1 was iodinated in house as previously described [9]. All cell
culture reagents were obtained from Sigma-Aldrich (Dorset, UK)
or Invitrogen (Life technologies, Paisley, UK) unless otherwise
stated.
DNA Constructs Design
The wild type human GNRHR cDNA was modified to encode
an amino-terminal Hemagglutinin (HA) tag and cloned into
pcDNA3.1(+) (Invitrogen). The two GNRHR1 missense mutations
were prepared using a Phusion Site-Directed Mutagenesis Kit
(Finnzymes, Vantaa, Finland). Phosphorylated (59-end) sense and
antisense primers were as follows: (p.Pro282Arg; c.845 C.G)
Sense: 59- CTGCTGGACTCGCTACTACGTACT-39; Anti-
sense: 59-ACAGTAAAACTAGTGGCAAATGCAA-39; (Y323C;
c.968 A.G) Sense: 59- TCCATTAATCTGTGGA-
TATTTTTCTCTG-39; Antisense: 59-TCAAAGCATGGGTT-
TAAAAAGG-39. Expression construct sequences were confirmed
with Sanger sequencing and receptor protein expression was
verified by immunocytochemistry.
Cell Culture, Transfection and Rescue Treatment
Wild type or mutant GNRHR1 constructs were transiently
transfected into COS-7 (ATCC CRL-1651) cells by transfection
using electroporation with a Gene Pulser (Bio-Rad Laboratories,
Hertfordshire, UK) at 230 V, 950 mF with 15 mg of DNA/0.4 cm
cuvette (1.56107 cells; 0.7 mL). To assess rescue of receptor
trafficking, either NBI-42902 (1 mM) or DMSO (vehicle control)
was added immediately before plating into 24-well plates. Cells
were grown for 28 h in Complete Medium (Dulbecco’s modified
Eagle’s Medium (DMEM) supplemented with 10% fetal bovine
serum, antibiotics and 2 mM L-glutamine) and then washed
(4630 min each) with Wash Medium (HEPES-DMEM supple-
mented with 2% DMSO, 0.1% bovine serum albumin and
penicillin/streptomycin). The Wash Medium was removed and
the cells were further incubated with the appropriate medium (as
mentioned below) overnight (,16 h) and then washed again
before the radioligand binding and IP accumulation assays were
performed.
Whole Cell Competitive Radioligand Binding Assays
Radioligand binding assays were performed on intact COS-7
48 h after transfection following the treatment with or without
1 mM NBI-42902. After the first round of washing (28 h post-
transfection), Complete Medium was added to cells and further
grown overnight. In the morning, the cells were washed again
and intact cells were incubated with radiolabeled GnRH analog
([125I]-His5-D-Tyr6-GnRH1, 100,000 cpm/well) and graded
concentrations of unlabeled GnRH1, prepared in Binding
Buffer (HEPES-DMEM supplemented with 0.1% BSA), for
4 h at 4uC. After incubation, free radioligand was removed
from the cells by two rapid washes with ice-cold PBS and the
cells were solubilized with NaOH (0.1 M). The radioactivity was
determined using a WizardTM 1470 automatic gamma counter
(Perkin Elmer).
Inositol Phosphate Accumulation Assays
Measurements of GnRH-elicited IP accumulation were per-
formed in COS-7 cells 48 h after transfection following incubation
with or without 1 mM NBI-42902. After the first round of washing
at 28 h, Labeling Medium (inositol-free DMEM supplemented
with 1% dialyzed heat-inactivated fetal calf serum, antibiotics and
2 mM L-glutamine with 0.5 mCi/well of myo-[2-3H]Inositol
[Perkin Elmer, Buckinghamshire, UK]) was added and the cells
were further grown overnight. In the morning, the cells were
washed again and incubated with IP Medium (HEPES-DMEM
supplemented with 0.1% bovine albumin and 10 mM LiCl) for
30 min at 37uC and then stimulated with graded concentrations of
GnRH1 in IP Medium for 1 h at 37uC. Reactions were
terminated by removal of ligands and the cells were lysed with
200 ml of ice-cold formic acid (0.1 M). Quantification of total 3H-
labeled inositol phosphates from cellular extracts was performed
by the multiwell filtration method [10].
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Confocal Microscopy
COS-7 cells were electroporated (as described previously),
diluted in Complete Medium, seeded on poly-D-lysine coated glass
coverslips and grown for 48 h at 37uC. Cells were then washed
with ice-cold PBS and fixed with 4% paraformaldehyde for
10 min at room temperature, washed 3x with PBS, permeabilized
with 0.3% Triton X-100, washed 1x with PBS, and blocked with
Blocking Solution (PBS containing 10% normal donkey serum and
0.5% NEN block [Perkin Elmer, UK]) for 45 min at room
temperature. The cells were then incubated with rabbit anti-HA
primary antibody (ab9110, 1:5000, Abcam UK) for 2 h at 37uC
and then Alexa FluorH 488 conjugated donkey anti-rabbit
secondary antibody (Invitrogen, 1:400) for 1 h at 37uC. Cells
were counterstained with Hoechst 33342 (10 mg/ml) for 10 min at
room temperature and visualized using a Zeiss LSM510 Meta
inverted confocal laser scanning microscope (Carl Zeiss, Herts,
UK) equipped with a (DAPI/FITC/Rhod) filter set and a 63x oil
objective lens (Zeiss). The exposure settings were determined
empirically for each channel from control background and
unchanged within an experiment. Images were acquired at
102461024 pixel resolution and using 0.3 mm Z-stacks. Image
stacks were imported into Image J software where average
intensity images were produced after which scale bars were
embedded and files were saved in tiff format.
Presentation of Data and Statistics
For analyses of competitive radioligand binding and inositol
phosphate accumulation, data representing the mean 6 SEM
from at least three independent experiments (in which each data
point was measured in triplicate) were plotted using a one-site
model of binding using Prism 5.0 (GraphPad Software, San Diego,
CA). The data from mutant receptors and treatment with NBI-
42902 were expressed relative to a wild type control included in
each transfection. Sigmoidal dose-reponse curves were fitted to the
relevant data sets using non-linear regression and IC50, Bmax,
EC50, and Emax values were determined. The effect of NBI-42902
treatment on each receptor was analyzed for statistical significance
by Student’s t test and indicated by an asterisk in the tables
(P#0.05).
Results
Clinical Evaluation
The proband (subject II-4, Fig. 1) was a Caucasian French man
born to non-consanguineous eugonadal French parents. He was
referred to the clinic at 18 years of age for absent pubertal
development. Physical examination showed typical signs of
hypogonadism, with small intrascrotal testes (2 mL). He had very
low levels of plasma testosterone, serum LH and FSH and
displayed a blunted response to GnRH challenge (Table 1). His
height was 183 cm and his weight was 65 kg. He had a normal (46
XY) karyotype.
The proband’s two older affected brothers (subjects II-1 and
Subject II-3, Fig. 1) were also referred to the clinic for absent
pubertal development at 21 and 20 years of age, respectively. They
both presented with typical aspects of hypogonadism in which the
diagnosis of congenital hypogonadotropic hypogonadism was
made given the concomitant very low serum testosterone, low
gonadotropin levels and the blunted gonadotropin response (LH
and FSH) after GnRH stimulation (Table 1).
All the male patients studied here had normal pituitary glands
and olfactory bulbs when visualized using magnetic resonance
imaging (MRI) and had a normal sense of smell when assessed
with olfactometry. They all had no renal or craniofacial
abnormalities and had normal circulating iron, ferritin, and
prolactin levels. Their adrenal and thyroid function was normal
and had otherwise normal pituitary function. None had any other
phenotypic abnormality.
Molecular Analysis
The proband was screened for mutations in genes known to be
associated with CHH including GNRH1, GNRHR1, KISS1,
KISS1R, TAC3 and TACR3 and those known to be associated
with Kallmann syndrome FGFR1, PROK2 and PROK2R. Analysis
of these genes were performed as previously reported [6,11–14]. In
addition, two genes responsible for the X-linked forms of
Kallmann syndrome and CHH associated with adrenal hypoplasia
congenita (KAL1 and NR0B1, respectively) were also screened as
previously reported [13,15].
The nucleotide sequences for GNRH1, KISS1, KISS1R, FGFR1,
PROK2, PROK2R, KAL1 and NR0B1 exons and intron-exon
boundaries were identical to reference sequences, but we identified
two novel missense mutations in the gene encoding the GNRH
receptor (GNRHR1: NM_000406.2; HGNC: 4421), see Figure 2.
The proband’s DNA profile showed two heterozygous mutations,
one mutation was a C-to-G transversion at cDNA nucleotide 845
(c.845C.G) leading to an amino acid substitution at residue 282
of proline for arginine (p.282P.R) and the other mutation was A-
to-G transition at cDNA nucleotide position 968 (c.968A.G)
leading to a substitution at residue 323 of tyrosine for cysteine
(p.323Y.C). Subsequently all family members, including the two
parents, were screened for GNRHR1 mutations and the pedigree
was determined (Fig. 1). Pro282Arg and Tyr323Cys GNRHR1
mutations were present in all the proband’s affected brothers but
not in his unaffected sister.
The SIFT protein database (sift.jcvi.org) sorts tolerant from
intolerant amino acid changes by comparing residues at equivalent
positions from different species and assigns a probability of
whether a given change is likely to be functional or inactivating.
Querying this database with the two novel GNRHR1 mutations
predicted that substitution at both positions, Pro282 and Tyr323,
with any other amino acid would be damaging to the receptor
function giving both a sift score of 0, where scores ,0.05 are
predicted to be deleterious.
The molecular impact of these two novel GnRHR mutations
was tested in vitro by expressing each mutant construct in COS-7
cells. When transfected cells were incubated with high concentra-
tions of radiolabeled GnRH1 in the absence of unlabeled ligand,
maximal binding to cells expressing Pro282Arg or Tyr323Cys was
absent or considerably reduced compared to cells expressing the
wild type receptor (Fig. 3 and Table 2). The Tyr323Cys mutant
displayed a small increase in binding affinity but maximal
radioligand binding was 4565% of that exhibited by cells
expressing the wild type receptor. Pretreatment of cells expressing
the Tyr323Cys mutant with NBI-42902 significantly increased
maximal radioligand binding to 7166% of wild type levels but had
no effect on cells expressing the Pro282Arg mutant.
To validate the rescue treatment protocol and to serve as
a positive control, the binding and IP responses of the GnRH
receptor mutant Glu90Lys was assayed with and without NBI-
42902 pretreatment. Previous studies have shown the ability to
rescue the maximal binding and IP responses of the Glu90Lys
mutant to wild type levels with another cell permeant GnRH
antagonist, IN3 [16]. In the absence of NBI-42902 treatment,
binding was absent from cells expressing the Glu90Lys mutant but
NBI-42902 pretreatment restored maximal binding above wild
type levels (13468%).
CHH Arising from Novel GnRH Receptor Mutations
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Figure 1. Pedigree showing two heterozygous mutations (Pro282Arg and Tyr323Cys) in the gene encoding hGNRHR1
(NM_000406.2; NP_000397.1). A C-to-G transversion at cDNA nucleotide 845 (c.845C.G) and a A-to-G transition at cDNA nucleotide position
968 (c.968A.G) leading to a substitution of Proline at residue 282 for Arginine (p.282P.R) and a substitution of Tyrosine at residue 323 for Cysteine
(p.323Y.C). Upper panel: Heterozygous Tyr323Cys and wild type allele in unaffected father (I-1); Heterozygous Pro282Arg and wild type allele in
unaffected mother (I-2); Bottom panel: Homozygous wild type alleles in an unaffected sister (II-2); Compound heterozygous Pro282Arg and Tyr323Cys
brothers (II-1, II-3) and proband (II-4 arrowed).
doi:10.1371/journal.pone.0038456.g001
Table 1. Clinical and hormonal characteristics of family members.
Subject (see Fig. 1)
(GNRHR1 genotype)
I-1 (Tyr323Cys/
WT)
I-2 (Pro282Arg/
WT)
II-1 (Tyr323Cys/
Pro282Arg) II-2 (WT/WT)
II-3 (Tyr323Cys/
Pro282Arg)
II-4 (Tyr323Cys/
Pro282Arg)
Sex/age at initial
evaluation (years)
M/47 F/44 M/21 F/34 M/20 M/18
Spontaneous puberty yes yes no yes no no
Clinical examinationa Eugonadic; Penis:
14 cm length;
TV:19 mL
Eugonadic;
Spontaneous
regular menses;
4 Spontaneous
pregnancies
Hypogonadic; Penis:
4 cm length; TV:
2 mL, Intrascrotal
Eugonadic;
Spontaneous
regular menses;
4 Spontaneous
pregnancies
Hypogonadic; Penis:
6 cm length; TV:
3 mL, Intrascrotal
Hypogonadic; Penis:
3 cm length; TV:
2 mL, Intrascrotal
Sense of smell
(olfactometry)
– – normal – normal normal
Ta,b (ng/mL)/E2 (pg/mL) 5.7/2 2/47 0.2/2 2/62 0.4/2 0.15/2
LHa,b (IU ; basal/
stimulatedc)
3.8 3.8 0.3/0.6 5.7/2 0.7/2 0.5/0.8
FSHa,b (IU ; basal/
stimulatedc)
4.3 3.9 0.9/0.8 4.4/2 0.9/2 0.8/1.1
Inhibin B 186 – 33 – 26 39
Other pituitary
functionsd
– – normal – normal normal
Pituitary and olfactory
bulbs MRI
– – normal – normal normal
WT: wild type GNRHR1; TV: mean testicular volume (normal range in post pubertal men: 12–30 mL). MRI: magnetic resonance imaging.
aAt diagnosis before therapy in affected patients.
bNormal range in adults, basal LH: 2.8–7.1 IU/L; basal FSH: 2.4–7.0 IU/L, in post menopausal women: LH: 14–132 IU/L, FSH: 28–171; T in men: 2.8–9.0 ng/mL, Inhibin B in
men: 98–366); E2 in women: 24–90 pg/mL (early follicular phase).
cGnRH: 100 mg intravenous.
dNormal cortisol and GH under hypoglycemia challenge test. Normal free T4 and TSH, normal prolactin.
- : Not done.
doi:10.1371/journal.pone.0038456.t001
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The capacity of each mutant receptor to transduce an
intracellular signal by coupling to phosphatidyl inositol hydrolysis
was measured by quantifying ligand induced intracellular accu-
mulation of 3H-inositol phosphates (IP) (Table 3). In the absence of
NBI-42902 pretreatment, both non-rescued mutants lacked the
ability to generate significant IP accumulation after incubation of
Figure 2. DNA sequence traces and associated amino acid changes in the hGNRHR1 gene of the propositus. A, Forward sequence traces
of the propositus encompassing the heterozygotic mutations in GNRHR, c.968A.G and c.968A.G. Nucleotides changes are indicated by arrows.
MUT, Mutant; WT, wild type. B, The resultant amino acid changes are presented for the mutants compared with wild type and are presented within a 2
dimensional GNRHR schematic.
doi:10.1371/journal.pone.0038456.g002
Figure 3. Competitive binding characteristics for Pro282Arg
and Tyr323Cys hGNRHR1mutants compared to wild type. COS-7
cells were transfected with the expression vector indicated and then
grown in the presence of pharmacoperone (NBI-42902) or vehicle
(DMSO), washed and then subjected to competitive binding assays
using the GnRH1 analog ([125I]-His5-D-Tyr6-GnRH1) and graded con-
centrations of unlabeled GnRH1. The degree of mutant receptor
binding was compared to cells expressing the wild type receptor.
doi:10.1371/journal.pone.0038456.g003
Table 2. In vitro Radioligand Competition Binding Assay.
+NBI-42902
pIC50 (nM) Bmax pIC50 (nM) Bmax
Wild type 8.5460.04
(2.88)
10062 8.5660.17
(2.75)
93613
Glu90Lys nb nb 8.2160.06
(6.17)
13468*
Pro282Arg nb nb nb nb
Tyr323Cys 8.8560.11
(1.41)
4565 8.9060.10
(1.26)
7166*
Ligand binding affinity (pIC50) were measured on intact COS-7 cells transfected
with wild type and mutant receptors by competition binding using 125I-His5-D-
Tyr6-GnRH1.
Bmax =% of total radioligand bound were expressed relative to wild type
receptor without NBI-42902.
nbNo measurable binding.
Values are mean 6 SEM of three or more independent experiments, converted
to nM (in parentheses).
Significant difference of NBI-42902 treatment on Bmax is represented by an
asterisk * (p,0.05).
doi:10.1371/journal.pone.0038456.t002
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cells with graded concentrations of GnRH1. Even after NBI-
42902 pretreatment, the Pro282Arg mutant was unable to
generate IP turnover at any GnRH1 concentration whereas this
treatment substantially increased maximal IP accumulation to
1663% of the wild type response in cells expressing the
Tyr323Cys mutant (Fig. 4, Table 3). Using NBI-42902 pre-
treatment, maximal IP response of the Glu90Lys mutant increased
to 5963% of wild type levels.
To evaluate the cellular distribution and assess the degree of
intracellular retention of the mutant receptors compared to wild
type, we performed immunocytochemical studies on permeabi-
lized and non-permeabilized heterologously expressing COS-7
cells. In permeabilized cells Pro282Arg and Tyr323Cys mutants
were expressed predominantly in the perinuclear region when
compared to wild type receptor (Fig. 5, upper panel), suggesting
greater misfolding and cellular retention. In non-permeabilized
cells, wild type GnRHR was located at the plasma membrane at
a higher proportion than both mutants (Fig. 5, lower panel). Thus
these ICC data confirm the substitution of Pro282 by Arginine and
Tyr323 by Cysteine impair the proper membrane targeting of the
GnRH receptor.
Discussion
In the family studied here, the male proband was the third son
in a kindred of four in which he and his two brothers suffer
complete nCHH whilst the sister was unaffected. This observation
led us to suspect first an X-linked mode of inheritance of the
disease. After excluding mutations in KAL1 and NR0B1, which are
associated with X-linked forms of CHH, genes associated with
autosomal normosmic CHH or Kallmann syndrome were then
screened. We found two novel non-synonymous missense muta-
tions in the gene encoding the GnRH receptor (one mutation
affecting each allele). All three affected male patients were
compound heterozygous for each mutation whereas the unaffected
parents possessed one mutant (either Pro282Arg or Tyr323Cys)
and one wild type allele. Whilst the pattern of inheritance
appeared X-linked, genetic analysis of this family formally
confirmed an autosomal recessive transmission in agreement with
previous published cases of GNRHR loss-of-function mutations
[4], which confirms that one copy of the wild type GNRHR1 gene
is sufficient for normal gonadotrope function, ruling out
haploinsufficiency. In view of the rare but sometimes oligogenic
inheritance reported in CHH [17], we screened all other nCHH
candidate genes but only found the two GNRHR1 mutations,
suggesting these as the main contributors to the observed nCHH
phenotype in this family.
The GNRH receptor is a 328 amino acid tail-less G protein-
coupled receptor (GPCR) encoded by a three-exon gene spanning
18.7 kb of chromosome 4q21.2 [2]. The frequency of inactivating
mutations in GNRHR1 is very low with only 22 other natural
mutations reported to cause HH identified to date (p.Asn10Lys
[18,19], p.Gln11Lys [20], p.Thr32Ile [5,19,21,22], p.Glu90Lys
[5,19,23,24], p.Thr104Ile [25], p.Gln106Arg [11,19],
p.Tyr108Cys [25], p.Ala129Asp [19,26], Arg139His [18,19],
Arg139Cys [27], p.Pro146Ser [28], p.Ser168Arg [29],
p.Ala171Thr [19,30], p.Cys200Tyr [5,19,21], p.Ser217Arg [31],
p.Arg262Gln [11,19], p.Leu266Arg [5,19,21,22], p.Cys279Tyr
[5,19,21,22], p.Pro282Arg (described here), p.Tyr284Cys
[19,32,33], p.Leu314X [19,34], p.Pro320Leu [20], p.Tyr323Cys
(described here) and a splice junction mutation at the intron 1–
exon 2 boundary [35]). As these 24 mutations are distributed
throughout the GNRHR1 gene a hotspot for mutations does not
seem to exist.
Like other GPCRs, this peptide receptor is folded into seven
transmembrane domains (TMDs) linked by alternating intracellu-
lar and extracellular loops. Natural inactivating-mutations have
contributed to understanding the structure-function relationships
necessary for the configuration and stable folding of the receptor,
ligand binding, receptor activation and intracellular signal
coupling (for review see [2]). Depending on the affected domain,
these natural mutations can be classified as either partial-loss or
Table 3. In vitro [3H]-Inositol Phosphate Accumulation Assay.
+NBI-42902
pEC50 (nM) Emax pEC50 (nM) Emax
Wild type 9.1660.12
(0.69)
10064 9.2060.23
(0.63)
11569
Glu90Lys ns ns 8.8260.14
(1.51)
5963*
Pro282Arg ns ns ns ns
Tyr323Cys ns ns 8.7660.43
(1.74)
1663*
IP responses (pEC50) were measured in COS-7 cells transfected with wild type
and mutant receptors.
Emax =% of maximal IP responses were expressed relative to wild type receptor
without NBI-42902.
nsNo measurable stimulation.
Values are mean 6 SEM of three or more independent experiments, converted
to nM (in parentheses).
Significant difference of NBI-42902 treatment on Emax is represented by an
asterisk * (p,0.05).
doi:10.1371/journal.pone.0038456.t003
Figure 4. Inositol phosphate accumulation in COS-7 cells
expressing wild type GNRHR1 and the two hGNRHR1 mutants,
Pro282Arg and Tyr323Cys. COS-7 cells were transfected with the
expression vector indicated and then grown in the presence of
pharmacoperone (NBI-42902) or vehicle (DMSO) and then washed
before the addition of myo-[2-3H]Inositol. After 16 h the cells were
washed again and then incubated for 1 h with graded concentrations
of GnRH1. The amount of intracellular accumulation of labeled inositol
phosphates in the two mutant expressing COS-7 cells was compared to
cells expressing the wild type receptor.
doi:10.1371/journal.pone.0038456.g004
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complete loss-of-function. The two novel mutations identified
herein (Pro282Arg and Tyr323Cys) apparently disrupt the
functioning of TMD6 and TMD7, respectively, via two distinct
mechanisms.
The novel Pro282Arg mutation resides in a site in the sixth
TMD a-helix in which the proline residue is highly conserved
in the rhodopsin family of GPCRs. Pro6.50 (superscripts in this
form indicate Ballesteros-Weinstein numbering for conserved
GPCR residues [36]) is found at the homologous position not
only in GnRH receptors from different species (from inverte-
brates to humans) but is 100% conserved in family A GPCRs
[37]. The crystal structure of rhodopsin and other model
GPCRs have revealed that TMD6 is kinked due to this
conserved proline [38,39]. Proline residues weaken transmem-
brane a-helices and kink protein structures due to irregular
backbone hydrogen bonding and the presence of a bulky
pyrrolidine ring. In rhodopsin and other family A GPCRs
Pro6.50 is thought to act as a pivot around a cluster of flexible
aromatic residues (Phe6.44, Trp6.48, Tyr6.51 and Tyr6.52 in the
human GNRHR1). In this model, toggling of Trp6.48 modulates
the bend angle of TMD6 around Pro6.50 so that receptor
activation transduces large conformational changes at the
cytoplasmic interface of TMD6 [37,38,40]. Modeling the wild
type human GNRHR1 in the active conformational state
confirmed that disrupted intramolecular interactions involving
TMD6 (Cys6.47 and Asn7.45, and between Met3.43 and Phe6.40)
led to a small clockwise rotation (viewed from the extracellular
side) of the intracellular portion of TMD6 around the Pro6.50
hinge [41]. In addition to being central to the toggle-hinge
mechanism, Pro6.50 is neighboring a hydrophobic pocket formed
by Trp6.48(280), Tyr6.51(283), Tyr6.52(284), Phe5.43(216) and
Tyr3.37(126) [42] and substitution to arginine would not only
drastically disrupt the proline-induced structural constraints but
would also change the native charge environment due to the
basic arginine side chain.
The Pro282Arg mutation is the third amino acid mutation to be
found in TMD6 of GNRHR, but is structurally and functionally
the most severe. The complete lack of both binding and inositol
phosphate accumulation even when treated with a receptor
trafficking-rescue regimen can be explained by destruction of the
global receptor structure and/or ligand binding pocket, and/or
failure to be targeted efficiently to the plasma membrane. Our
immunocytochemical analysis detected mutated Pro282Arg re-
ceptor protein throughout the cell and some at the cell membrane
(Fig. 5) indicating that a proportion of receptor is able to escape
ER quality control mechanisms. This suggests that disruption of
the active receptor conformation and/or decreased ligand binding
pocket is the principal cause for the complete-loss-of-function of
this mutant receptor. The other previously described TMD6
mutants (Cys279Tyr and Tyr284Cys) have either absent binding
and IP activation [22] or decreased binding and IP activation,
respectively [32], but unlike Pro282Arg, their function was rescued
to some extent after pharmacoperone (IN3) treatment [5,19,22].
The second novel mutation identified in our patients
(Tyr323Cys) resides towards the intracellular portion of TMD7
within the highly conserved N/DPxxY motif. Movements essential
for receptor activation promote the interaction of Tyr323 with the
side chain of Arg3.50 (TMD3) [43,44]. This interaction stabilizes
the active receptor conformation and mediates ligand-induced
signal transduction [45,46]. The essential role of Tyr323 in G
protein-signal transduction has been evidenced by mutation of
Tyr323 to alanine which increased receptor expression 2.5-fold
compared to wild type but resulted in poor Gaq/11 coupling
[45,46]. Interestingly, substitution of Tyr323 to Phe, which
preserves the aromatic nature of the residue but eliminates the
side chain hydroxyl-group resulted in normal G protein-activation
Figure 5. Subcellular localization of heterologously expressed GNRHR1 and mutants, Pro282Arg and Tyr323Cys, in permeabilized
and non-permeabilized cells. COS-7 cells were transfected with the expression vector indicated and the immunoreactivity was assessed using
indirect methods as described in the methods and materials section. The nuclei are counterstained by Hoechst (blue) and immunofluorescence of the
HA-conjugated receptor is shown in red. Z-stack projection of GNRHR distribution in permeabilized (upper panel) and non-permeabilized (lower
panel) cells obtained by confocal microscopy. White arrows indicate plasma membrane expression. Scale bar represents 15 mm.
doi:10.1371/journal.pone.0038456.g005
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as assayed by induced inositol phosphate accumulation [45]. Our
results corroborate the importance of maintaining this aromatic
side chain for active G protein signaling as the Tyr323Cys
mutation, which substitutes the aromatic side chain with one that
is hydrophobic and polar, was able to bind radioligand but
completely lacked ligand induced inositol phosphate accumula-
tion. After treatment with NBI-42902, where plasma membrane
expression of the mutant receptor was increased to 71% of wild
type levels, only small levels of IP accumulation was detected (16%
of wild type levels) indicating the impairment of G protein-
activation is compounded by ineffective plasma membrane
routing.
When compared to the other naturally occurring TMD7
mutants, the Tyr323Cys mutation is the least severe when assayed
in vitro. Both, Leu314X, a nonsense truncation mutation, and
Pro320Leu, a missense mutation, lacked GnRH binding and
production of inositol phosphates in response to GnRH stimula-
tion [20,47].
The hormonal profiles of our three affected patients harboring
the Pro282Arg/Tyr323Cys compound mutations support the
findings that these mutated GnRH receptors lack residual
biological activity and present with complete CHH. In two of
the affected males there was absent gonadotropin response after
GnRH stimulation. The clinical phenotype of our patients
mirrored the severity of their hormonal deficiency with small
prepubertal testicular volume and underdeveloped external
genitalia. Micropenis and small intrascrotal testes, sometimes
cryptorchid, are reported in male patients with GNRHR1
mutations [48], likely reflecting insufficient secretion of gonado-
tropins and testosterone during the prenatal period.
In conclusion, we have identified two novel GNRHR gene
mutations present in members of a family of French Caucasian
origin. The severe phenotypic features of complete normosmic
congenital hypogonadotropic hypogonadism in compound het-
erozygous patients demonstrate the deleterious effect of both
mutations, one of which can be classified as a partial and the other
a full loss-of-function mutation in vitro.
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